recent publications
-
academic article
- DeMartino, J. K. NCCN Work Group Report: Emerging issues in tissue allocation Journal of the National Comprehensive Cancer Network 2016 14:265-271 PMID:26957613
- DeMartino, J. K., Larsen, J. K. Data needs in oncology: making sense of the big data soup Journal of the National Comprehensive Cancer Network 2013 11:S1-S12
- DeMartino, J. Evolving policy issues in oncology: revisiting biosimilars and molecular testing Journal of the National Comprehensive Cancer Network 2013 11:1174-1177 PMID:24029129
- DeMartino, J. K. Measuring quality in oncology: challenges and opportunities Journal of the National Comprehensive Cancer Network 2013 11:1482-1491 PMID:24335683
-
Connelly, S., DeMartino, J. K., Boger, D. L., Wilson, I. A.
Biological and structural evaluation of 10R- and 10S-methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase
Biochemistry
2013
52:5133-5144
DOI:10.1021/bi4005182
PMID:23869564
PMCID:PMC3823235
- DeMartino, J. K., Larsen, J. K. Equity in cancer care: pathways, protocols, and guidelines Journal of the National Comprehensive Cancer Network 2012 10:S1-S9 PMID:23042831
- DeMartino, J. K. The Physician Payment Sunshine Act Journal of the National Comprehensive Cancer Network 2012 10:423-424
- DeMartino, J. K. Biosimilars: approval and acceptance? Journal of the National Comprehensive Cancer Network 2011 9:S6-S9 PMID:21357668
- Zelenetz, A. D., Ahmed, I., Braud, E. L., Cross, J. D., Davenport-Ennis, N., Dickinson, B. D., Goldberg, S. E., Gottlieb, S., Johnson, P. E., Lyman, G. H., Markus, R., Matulonis, U. A., et al. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives Journal of the National Comprehensive Cancer Network 2011 9:S1-S22 PMID:21976013
- Engstrom, P. F., Bloom, M. G., Demetri, G. D., Febbo, P. G., Goeckeler, W., Ladanyi, M., Loy, B., Murphy, K., Nerenberg, M., Papagni, P., Robson, M., Sweetman, R. W., et al. NCCN Molecular Testing White Paper: effectiveness, efficiency, and reimbursement Journal of the National Comprehensive Cancer Network 2011 9:S1-S16 PMID:22203777
- DeMartino, J. K. Changes to Medicare Part D: who benefits? Journal of the National Comprehensive Cancer Network 2010 8:S4-S6 PMID:20947723
- Danielson, E., DeMartino, J., Mullen, J. A. Managed care & medical oncology: the focus is on value Journal of the National Comprehensive Cancer Network 2010 8:S28-S37 PMID:20947721
- Johnson, P. E., Dahlman, G., Garg, R., Gottlieb, S., Hoffman, J. M., Howell, P., Jahanzeb, M., Johnson, S., Mackler, E., Rubino, M., Sarokhan, B., Stewart, F. M., et al. NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: recommendations for stakeholders Journal of the National Comprehensive Cancer Network 2010 8:S7-S27 PMID:20947724
- Li, E. C., DeMartino, J. Preliminary report: the development of the NCCN Comparative Therapeutic Index as a clinical evaluative process for existing data in oncology Journal of the National Comprehensive Cancer Network 2010 8:S1-S9 PMID:20870621
-
Mileni, M., Garfunkle, J., DeMartino, J. K., Cravatt, B. F., Boger, D. L., Stevens, R. C.
Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures
Journal of the American Chemical Society
2009
131:10497-10506
DOI:10.1021/ja902694n
PMID:19722626
PMCID:PMC2739126
-
DeMartino, J. K., Hwang, I., Connelly, S., Wilson, I. A., Boger, D. L.
Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase
Journal of Medicinal Chemistry
2008
51:5441-5448
DOI:10.1021/jm800555h
PMID:18686942
PMCID:PMC2559975
-
DeMartino, J. K., Garfunkle, J., Hochstatter, D. G., Cravatt, B. F., Boger, D. L.
Exploration of a fundamental substituent effect of α-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hydrolase
Bioorganic & Medicinal Chemistry Letters
2008
18:5842-5846
DOI:10.1016/j.bmcl.2008.06.084
PMID:18639454
PMCID:PMC2582052
-
DeMartino, J. K., Boger, D. L.
Glycinamide ribonucleotide transformylase (GAR Tfase) as a target for cancer therapy
Drugs of the Future
2008
33:969-979
DOI:10.1358/dof.2008.33.11.1247542
-
DeMartino, J. K., Hwang, I., Xu, L., Wilson, I. A., Boger, D. L.
Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase
Journal of Medicinal Chemistry
2006
49:2998-3002
DOI:10.1021/jm0601147
PMID:16686541
PMCID:PMC2531195